I will run from this stock when and if the Thyroid, Rosacea, AH studies, etc., come back negative. This one study was poorly conducted in many ways. Dosing was not appropriate, age group was not appropriate, and does not address inflammation anywhere. Anatabine helps with excess inflammation, which is not usually present in 18 to 22 year olds. An older age group would have probably yielded different results. Muscle recovery is subjective, and again, much easier achieved by a young age group. Making this one study out to be a killer to STAR just shows desperation on the shorts part. I am in this for the long haul, and all this nitpicking will not make me, or lots of other longs run. Keep bashing if you must, I'll just keep adding at bargain prices. Again, I use AnataBloc and know it works.
